Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-12-17 4:06 pm Unchanged | 13G | Cardiff Oncology Inc. CRDF | COMMODORE CAPITAL LP | 0 0.000% | 0 (Unchanged) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Cardiff Oncology Inc. CRDF | BlackRock Inc. BLK | 2,735,581 5.900% | 0 (Unchanged) | View |
| 2024-10-24 2:02 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | BlackRock Inc. BLK | 2,735,581 5.900% | 2,063,614 (+307.10%) | View |
| 2024-02-06 4:01 pm Sale | 13G | Cardiff Oncology Inc. CRDF | ACORN BIOVENTURES L.P. | 1,946,762 4.200% | -1,096,411 (-36.03%) | View |
| 2023-02-14 12:47 pm Sale | 13G | Cardiff Oncology Inc. CRDF | CAXTON CORP | 983,607 2.200% | -2,495,733 (-71.73%) | View |
| 2023-02-09 09:23 am Sale | 13G | Cardiff Oncology Inc. CRDF | JANUS HENDERSON GROUP PLC JHG | 0 0.000% | -3,523,012 (Position Closed) | View |
| 2023-01-26 1:30 pm Unchanged | 13G | Cardiff Oncology Inc. CRDF | ACORN BIOVENTURES L.P. | 3,043,173 6.380% | 0 (Unchanged) | View |
| 2023-01-26 1:28 pm Sale | 13D | Cardiff Oncology Inc. CRDF | ACORN BIOVENTURES L.P. | 3,043,173 6.380% | -2,947,666 (-49.20%) | View |
| 2022-07-08 4:56 pm Sale | 13G | Cardiff Oncology Inc. CRDF | BlackRock Inc. BLK | 671,967 1.600% | -1,860,281 (-73.46%) | View |
| 2022-02-14 4:13 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | CAXTON CORP | 3,479,340 8.100% | 380,893 (+12.29%) | View |
| 2022-02-14 4:04 pm Sale | 13G | Cardiff Oncology Inc. CRDF | Corriente Advisors LLC | 0 0.000% | -2,000,000 (Position Closed) | View |
| 2022-02-11 7:12 pm Sale | 13G | Cardiff Oncology Inc. CRDF | Avidity Partners Management LP | 0 0.000% | -2,153,600 (Position Closed) | View |
| 2022-02-10 2:25 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | JANUS HENDERSON GROUP PLC JHG | 3,523,012 8.400% | 1,385,341 (+64.81%) | View |
| 2022-02-09 12:06 pm Sale | 13G | Cardiff Oncology Inc. CRDF | STATE STREET CORP STT | 693,445 1.650% | -1,855,327 (-72.79%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | BlackRock Inc. BLK | 2,532,248 6.000% | 2,532,248 (New Position) | View |
| 2021-11-19 4:02 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | PFIZER INC PFE | 2,411,575 5.750% | 2,411,575 (New Position) | View |
| 2021-02-16 3:30 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | CAXTON CORP | 3,098,447 8.800% | 1,140,204 (+58.23%) | View |
| 2021-02-16 06:18 am Purchase | 13G | Cardiff Oncology Inc. CRDF | Corriente Advisors LLC | 2,000,000 5.660% | 2,000,000 (New Position) | View |
| 2021-02-12 5:20 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | Opaleye Management Inc. | 1,662,500 4.710% | 414,500 (+33.21%) | View |
| 2021-02-12 3:06 pm Purchase | 13G | Cardiff Oncology Inc. CRDF | JANUS HENDERSON GROUP PLC JHG | 2,137,671 6.100% | 2,137,671 (New Position) | View |